APA (7th ed.) Citation

Dummer, R., Shapira, R., Pigozzo, J., Ascierto, P., Gaudy Marqueste, C., Portnoy, D., . . . Long, G. (2024). 1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma. Annals of Oncology, 35, S717. https://doi.org/10.1016/j.annonc.2024.08.1151

Chicago Style (17th ed.) Citation

Dummer, R., et al. "1083P KEYMAKER 02B: A Randomized Trial of Pembrolizumab (pembro) Alone or with Investigational Agents as First-line Treatment for Advanced Melanoma." Annals of Oncology 35 (2024): S717. https://doi.org/10.1016/j.annonc.2024.08.1151.

MLA (9th ed.) Citation

Dummer, R., et al. "1083P KEYMAKER 02B: A Randomized Trial of Pembrolizumab (pembro) Alone or with Investigational Agents as First-line Treatment for Advanced Melanoma." Annals of Oncology, vol. 35, 2024, p. S717, https://doi.org/10.1016/j.annonc.2024.08.1151.